H01642 | |
H番号 | H01642 |
名称 | 腎性貧血 |
概要 | Renal anemia is one of the most frequent complications of chronic kidney disease. Anemia leads to a decrease in oxygen delivery to vital organs, which is initially compensated for by tachycardia and cardiac hypertrophy, but eventually leads to the development of cardiovascular disease. Renal anemia is caused by the deficiency of endogenous erythropoietin (EPO) due to renal dysfunction. EPO is a glycoprotein hormone that has the role of the primary regulator of erythropoiesis. Formerly, treatment options were essentially limited to blood transfusions and androgen therapy, with its risks. However, since the late 1980s, the availability of recombinant human erythropoietin has revolutionized the management of renal anemia, and erythropoiesis-stimulating agents (ESAs) are now the mostly widely used drugs. |
カテゴリ | 泌尿器系疾患 |
ネットワーク | - |
病因遺伝子 | - |
病原体 | - |
環境要因 | - |
発癌物質 | - |
治療薬 | テストステロンエナント酸エステル [DR:D00958] メピチオスタン [DR:D01602] エポエチンアルファ [DR:D03231] エポエチンベータ [DR:D03232] ダルベポエチンアルファ [DR:D03651] エポエチンベータペゴル [DR:D09998] ロキサデュスタット [DR:D10593] ダプロデュスタット [DR:D10874] バダデュスタット [DR:D11078] モリデュスタットナトリウム [DR:D11273] エナロデュスタット [DR:D11523] |
コメント | - |
リンク | ICD-11: 3A71.2 ICD-10: N19 MeSH: D007676 |
文献 | PMID:26381503 著者 Mimura I, Tanaka T, Nangaku M タイトル How the Target Hemoglobin of Renal Anemia Should Be. 雑誌 Nephron 131:202-9 (2015) DOI:10.1159/000440849 PMID:16281953 著者 Eckardt KU, Kurtz A タイトル Regulation of erythropoietin production. 雑誌 Eur J Clin Invest 35 Suppl 3:13-9 (2005) DOI:10.1111/j.1365-2362.2005.01525.x PMID:26456375 著者 Kawahara K, Minakuchi J, Yokota N, Suekane H, Tsuchida K, Kawashima S タイトル Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. 雑誌 Nephrology (Carlton) 20 Suppl 4:29-32 (2015) DOI:10.1111/nep.12647 PMID:21930831 著者 Locatelli F, Del Vecchio L タイトル Erythropoiesis-stimulating agents in renal medicine. 雑誌 Oncologist 16 Suppl 3:19-24 (2011) DOI:10.1634/theoncologist.2011-S3-19 |